Phase II study of Osimertinib Treatment on EGFR T790M Cytology Positive NSCLC Patients (DETECTIVE study) - Phase II study of Osimertinib Treatment on EGFR T790M Cytology Positive NSCLC Patients (DETECTIVE study)

Kobe City Medical Center General Hospital Department of medical oncology0 个研究点目标入组 6 人开始时间: 2017年10月30日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Treatment history of osimertinib or other third-generation EGFR tyrosine kinase inhibitors (ex. ASP8273) 2) Patients who received other EGFR-tyrosine kinase inhibitors again after disease progression 3) Treatment history of immune checkpoint inhibitors 4) QTc >470 msec 5) Patients with interstitial pneumonia, pulmonary fibrosis or radiation pneumonitis on chest CT 6) Patients with history of drug-related interstitial lung disease 7) Patients with history of serious drug allergy 8) Patients with serious infection or other serious concomitant disease (ex. gastrointestinal bleeding) 9) Uncontrollable pleural effusion, ascites or pericardial effusion 10) Clinically problematic heart disease 11) Uncontrollable diabetes 12) Central nervous system metastasis with a clinical manifestation 13) Patients with active double cancer 14) Clinically problematic psychiatric disorders 15) Unhealed fracture or heavy wound 16) Pregnant or breast-feeding female patients, female patients who have a possibility of pregnancy and does not intend to use birth control till after 6 weeks after last administration or male patients who does not intend to use birth control till after 4 months after last administration 17) Patients judged to be ineligible for safe implementation of this trial by the investigators

发起方

Kobe City Medical Center General Hospital Department of medical oncology